Active, Not Recruiting
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
NCT07046182
- Conditions
- Angioimmunoblastic T-cell Lymphoma (AITL), Hemic and Lymphatic Diseases, Immune System Diseases, +5 more
- Locations
-
- The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China